Moon lander is lost on second bid at touchdown by Tokyo-based company

As scientists search for worlds that may be habitable for life, they've discovered a type that is common in the universe — but doesn't exist in our own solar system.
These enigmatic planets are called sub-Neptunes, which are larger than Earth but smaller than Neptune.
An April study catapulted one such world, named K2-18b, into the spotlight. Astronomers at the University of Cambridge claimed they detected molecules in the planet's atmosphere that might be biosignatures — markers of biological activity that could hint at past or present life.
Now, other groups of astronomers have looked at the same data and disagree with the findings, saying there is more to the story.
The twists and turns in the ongoing conversation around planet K2-18b showcase why the search for evidence of life beyond Earth is so difficult.
Indeed, persistence is everything when it comes to space investigation. 'Never quit the lunar quest' was the motto underpinning a high-stakes mission that aimed to touch down on the moon Thursday. But Tokyo-based Ispace lost contact with its vehicle at the time it should have landed.
The Resilience spacecraft was Ispace's second bid at a soft lunar landing. The company's previous try with the Hakuto-R lunar lander crashed into the moon in April 2023.
'This is our second failure, and about these results, we have to really take it seriously,' said Ispace CEO Takeshi Hakamada of the nail-biting attempt. Ispace has its work cut out for it, but it isn't giving up.
New research combining artificial intelligence with radiocarbon dating is changing the way scholars think about the Dead Sea Scrolls.
Bedouin shepherds first spotted the scrolls in 1947 within a cave in the Judaean Desert. Archaeologists then recovered thousands of scroll fragments, including the oldest copies of the Hebrew Bible, from 11 caves near the site of Khirbat Qumran.
'They completely changed the way we think about ancient Judaism and early Christianity,' said lead study author Mladen Popović, a dean at the University of Groningen in the Netherlands.
Scholars thought the roughly 1,000 manuscripts, written mostly on parchment and papyrus, ranged from the third century BC to the second century AD. But some of the scrolls, which serve as a crucial intellectual time capsule, could be much older, the new analysis suggests.
A World War I-era submarine was lost at sea off California's coast nearly 108 years ago, killing 19 crew members. Now, researchers from the Woods Hole Oceanographic Institution have captured never-before-seen deep-sea imagery of the wreckage.
The plague pandemic known as the Black Death killed at least 25 million people across medieval Europe over five years.
The culprit behind the disease is a bacterium called Yersinia pestis, which has led to three major plague outbreaks since the first century AD — and it still exists today.
How has the plague persisted for centuries? Changes to one gene in the bacterium created new, less deadly strains that kept hosts alive longer so it could keep spreading.
The weaker strains have since gone extinct, according to new research. But the findings could yield key clues to help scientists manage the current bacterium's dominant lineage, which is of the deadlier variety.
If you've ever walked through a fruit orchard, you might have been steps away from a living tower of worms.
That's what researchers from the Max Planck Institute of Animal Behavior and the University of Konstanz in Germany found when they inspected rotten pears and apples.
Hundreds of the microscopic worms, called nematodes, climbed on top of one another to form structures 10 times their size — even making a twisting 'arm' to sense the environment — leading scientists to question what's driving the behavior.
'What we got was more than just some worms standing on top of each other,' said senior study author Serena Ding, a Max Planck research group leader of genes and behavior. 'It's a coordinated superorganism, acting and moving as a whole.'
These stories will pique your curiosity:
— For over a century, astronomers thought the Milky Way and Andromeda galaxies would collide in 4.5 billion years, but new telescope observations may change that. However, another galaxy could entangle with ours sooner.
— Archaeologists who uncovered the remains of an ancient Mayan complex in Guatemala named the site after two humanlike rock figures that are believed to represent an 'ancestral couple,' according to the country's Ministry of Culture and Sport.
— A fossil of the earliest known bird that was kept in a private collection for decades has provided scientists with 'one 'Wow!' after another,' including the first flight feathers seen in an Archaeopteryx specimen, said Dr. Jingmai O'Connor, associate curator of fossil reptiles at the Field Museum.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Medscape

an hour ago

• Medscape

Novel GLP-1 Agonist Promotes Safe and Effective Weight Loss

Ecnoglutide, a novel glucagon-like peptide-1 (GLP-1) receptor agonist, was significantly more effective than placebo for inducing weight loss in adults with overweight or obesity, based on data from more than 600 individuals, results of the SLIMMER trial showed. In addition, ecnoglutide significantly improved other key cardiometabolic risk factors including waist circumference, blood pressure, lipid profile, A1c, fasting glucose, insulin level, and uric acid, while concurrently reducing liver fat content, said study author Linong Ji, MD, of Peking University People's Hospital, Beijing, China. "These benefits position ecnoglutide as a compelling therapeutic strategy for managing clinical obesity, especially in the context of metabolic dysfunction and associated steatotic liver disease (MASLD)," he noted. The results of the phase 3 randomized trial were presented here at the American Diabetes Association (ADA) 85th Scientific Sessions and simultaneously published in The Lancet Diabetes & Endocrinology . The new drug is distinct from other GLP-1 receptor agonists in its ability to selectively induce production of cyclic adenosine monophosphate (cAMP). Unlike unbiased GLP-1 therapies, ecnoglutide selectively activates cAMP signaling pathways while minimizing β-arrestin recruitment, which may explain its enhanced effectiveness for body weight reduction and sustained metabolic effects, Ji said in an interview. Weight Loss at All Doses The researchers randomized 664 overweight and obese Chinese adults to a weekly dose of 1.2 mg, 1.8 mg, or 2.4 mg of ecnoglutide or to placebo. The coprimary endpoints were percentage change in body weight and proportion of individuals with a reduction of 5% or more in body weight after 40 weeks. The study population included adults aged 18-75 years with overweight or obesity, defined as a BMI of 28 kg/m² or higher, or 24 kg/m² or higher with at least one weight-related comorbidity (prediabetes, hypertension, hyperlipidemia, MASLD, obstructive sleep apnea syndrome, or weight-bearing joint pain), but without type 1 or 2 diabetes. The mean age of participants was 34.2 years, and half were female. Individuals in the ecnoglutide group had an average body weight loss of 9.1%, 10.9%, and 13.2% from baseline at 40 weeks at doses of 1.2 mg, 1.8 mg, and 2.4 mg, respectively, which was significantly greater at all dose levels than placebo (0.1%) ( P < 0.0001 vs placebo for all doses). In addition, significantly more patients in the ecnoglutide groups lost at least 5% of their body weight at week 40 compared to the placebo group (77%, 84%, 87%, and 16% in the 1.2-mg, 1.8-mg, 2.4-mg, and placebo groups, respectively). A key secondary efficacy endpoint was the percentage of individuals who achieved a body weight loss of at least 5% after 48 weeks; 78% to 93% of participants across the ecnoglutide groups achieved this endpoint, with the greatest changes at the higher doses. Ten individuals across the ecnoglutide groups discontinued the medication because of adverse events, the most common of which were mild-to-moderate gastrointestinal events. Treatment-emergent adverse events occurred in 93% of participants in each of the ecnoglutide groups and in 84% of the placebo group. Clinical Takeaways and Next Steps "Ecnoglutide not only represents a viable competitor in the GLP-1 analog market but also stands out with its potential to address the nonresponse limitations in obesity treatment while providing holistic metabolic benefits," Ji told Medscape Medical News . At least 10% of weight-loss patients fail to achieve clinically significant weight loss of at least 5%, he explained. Possible reasons for the lack of success include genetic polymorphisms, metabolic heterogeneity, treatment compliance, or differential receptor sensitivity, he noted. "Providing alternative treatment options with a high response rate is crucial for individuals nonresponsive to existing therapies," he said. The trial results mark a milestone in obesity therapeutics and are a significant achievement in weight management. "After 48 weeks of treatment, ecnoglutide achieved a 15.4% weight reduction, with 92.8% of patients attaining clinically meaningful weight loss," he emphasized. "Considering the high potency of ecnoglutide" and the safety data, "it might serve as a viable option for individuals who do not achieve sufficient weight reduction with existing GLP-1 receptor agonists at their approved doses or need to achieve a better reduction in body weight," he added. "I am confident and optimistic that we'll see more personalized treatment regimens for obesity." Looking ahead, patients in the ecnoglutide 1.8-mg and 2.4-mg groups continued to have weight loss at week 48 without reaching a plateau, indicating that even greater weight loss might be possible with extended ecnoglutide treatment in studies of longer duration, Ji told Medscape Medical News . "To confer the added clinical advantage, a study comparing the clinical effects of a biased GLP-1 analog with those of a pharmacokinetically-matched but balanced GLP-1 analog would be needed," he said. In an accompanying editorial, Tricia M-M Tan, PhD, of Imperial College, London, UK, wrote: "The development of biased GLP-1 receptor agonists has been met with enthusiasm from the pharmaceutical industry, but does this design feature really confer any added clinical advantage?" She agreed with Ji that a comparative study of "a biased GLP-1 analog with those of a pharmacokinetically-matched but balanced GLP-1 analog" is needed. "Only then will the clinical role of this design feature be clear," she said. However, "the clinical results from ecnoglutide are likely to be generalizable to other populations," given that the effects of GLP-1 analogs are similar when tested in patients of various ethnicities, she said, adding this may increase the global availability of GLP-1 treatments. Refining Molecules to Enhance Efficacy, Reduce Side Effects Although current therapies represent potent, effective options for obesity-modifying treatment, they have limitations, with heterogeneity of responses in terms of potency and tolerability, said Andrew Kraftson, MD, a specialist in endocrinology and internal medicine at the University of Michigan, Ann Arbor, in an interview. "Ecnoglutide continues the trend to refine these molecules to enhance efficacy and reduce side effects," he said. "When these types of peptides interact with cells, they activate certain receptors and generate a signal cascade that promotes the desired effects. However, the less specific the 'message', the less potent the signal. Additionally, side effects can be a result of the less-controlled message," he noted. As with tirzepatide, ecnoglutide was developed to produce a "biased" signal with the intent to provide greater control of the signal/message to increase the odds of weight control and reduce the odds of side effects, he explained. Although the current study was not a head-to-head comparison with other incretin mimetics, the similarity in weight loss efficacy to tirzepatide, a dual GLP-1/glucagon insulinotropic peptide agonist (GIP), was interesting and supports the biasing effect of the molecular manipulation as an effective strategy to refine incretin therapy, Kraftson told Medscape Medical News . From a clinical standpoint, the trend towards refining weight management therapy will benefit patients by expanding their options, said Kraftson. "It may also help us address the observed heterogeneity in clinical response we see in our patients and bring us closer to personalized medicine," he said. The current study's limitations, as acknowledged by the researchers, include the relatively short time period, small sample size, and lack of head-to-head comparison, said Kraftson. Additionally, the study differs from clinical practice in its dose escalation, he said. In practice, "we are not trying to get patients to a certain dose, we are trying to find the lowest, most tolerable, and sufficiently effective dose to achieve health goals; therefore, we may determine that dose titration needs to happen more slowly and/or that a low(er) dose may be sufficiently effective," he told Medscape Medical News . "The adverse event data for common gastrointestinal issues could potentially be better in clinical practice if mitigation strategies are employed," he said. "I would like to see future studies that go beyond finding the relative efficacy of doses to reporting on effective strategies for patient-dose matching."

Bloomberg

3 hours ago

• Bloomberg

Chinese Biotech Showcases Challenger to Eli Lilly's Obesity Drug

An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new challenger to blockbusters from Novo Nordisk A/S and Eli Lilly & Co. Hangzhou Sciwind Biosciences Co. said its drug, ecnoglutide, led to more than 15% weight loss after 48 weeks when given at the highest dose. Although the trial did not compare ecnoglutide directly with existing medicines, the results were very similar to what Lilly's Zepbound showed in previous China studies, Sciwind Chief Executive Officer Hai Pan said in an interview.

Yahoo

7 hours ago

• Yahoo

Science recap: This week's discoveries include new clues from the fossil skull of a mysterious human species

Editor's note: A version of this story appeared in CNN's Wonder Theory science newsletter. To get it in your inbox, sign up for free here. Tens of thousands of years ago, our species — Homo sapiens — mingled and interbred with other prehistoric humans: our distant cousins, the Neanderthals and Denisovans. Hundreds of Neanderthal fossils give us a good idea of their appearance, lives and relationships, but so little is known about Denisovans that they still don't have an official scientific name. Evidence of their existence has surfaced in faint traces, mapped by DNA markers that lurk in our own genetic makeup and confirmed by only a few fossil fragments. This week, however, a 146,000-year-old skull dredged out of a well in China in 2018 may just be a key missing piece to this cryptic evolutionary puzzle. The nearly complete skull did not match any previously known species of prehistoric human. But two new studies — which researchers say are among the biggest paleoanthropology papers of the year — detail how scientists were able to extract genetic material from the fossil and help unravel this biological mystery. The DNA sample taken from 'Dragon Man,' as the specimen is called, revealed that he was in fact related to Denisovans, early humans who are thought to have lived between roughly 500,000 and 30,000 years ago. The finding could be monumental, helping to paint a fuller picture of a time when our own species coexisted with other prehistoric humans. Astronomers have long grappled with the quandary of 'dark matter,' but plenty of enigmas surround regular matter as well. The proton-and-neutron-based atoms that we're familiar with are called baryonic matter. And this material is strewn between galaxies like intergalactic fog, making it extremely difficult to measure. Perhaps, that is, until now. A new study explains how scientists were able to observe the baryonic matter using the flashing of fast radio bursts. In a rare encounter, scientists have captured the first-ever footage of an elusive 3-foot-long squid alive in its deep-sea habitat. Fruit, flowers, birds and musical instruments decorated the walls of a luxury villa — part of a site the excavation team dubbed the 'Beverly Hills' of Roman Britain — before the building was razed roughly 1,800 years ago. The frescoes were painstakingly pieced together by experts from the Museum of London Archaeology. Han Li, senior building material specialist at MOLA, described the effort as a 'once in a lifetime' opportunity. Romans invaded modern-day Britain in AD 43 and established Londinium, the precursor to modern London. The occupation lasted for almost 400 years. Under the life-affirming glow of the sun, methane is a dangerous gas to be avoided. A heat-trapping chemical pollutant in Earth's atmosphere, methane exacerbates the climate crisis. But within the planet's deep recesses — thousands of feet below the ocean's surface off the US West Coast — the gas can be transformed into a nutritious meal. At least for spiders. Scientists say they've discovered three previously unknown species of sea spider living around methane seeps. In these marine habitats where sunlight can't reach, gas escapes through cracks in the seafloor and feeds bacteria that latch on to the spiders' exoskeletons. The bacteria convert carbon-rich methane and oxygen into sugars and fats the spiders can eat, according to a new study. The newfound Sericosura sea spiders may pass methane-fueled bacteria to their hatchlings as an easy source of food, the researchers suggest. Check out these other must-read science stories from the week: — A SpaceX Starship rocket exploded during a routine ground test on Wednesday. Explore how this and other recent setbacks may affect the company's Mars ambitions. — A tiny brown moth in Australia migrates some 600 miles at night using the stars for navigation — something only humans and birds were known to do before. — A hunt for ghostly cosmic particles found anomalous signals coming from Antarctic ice. A new detector could help scientists explain what they are. — Researchers used DNA to reconstruct the face of a prehistoric woman who lived around 10,500 years ago in what's now Belgium, suggesting that skin color already varied considerably among different populations. Like what you've read? Oh, but there's more. Sign up here to receive in your inbox the next edition of Wonder Theory, brought to you by CNN Space and Science writers Ashley Strickland, Katie Hunt and Jackie Wattles. They find wonder in planets beyond our solar system and discoveries from the ancient world.